Advertisement
Singapore markets open in 8 hours 51 minutes
  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     
  • S&P 500

    5,065.07
    +54.47 (+1.09%)
     
  • Dow

    38,455.41
    +215.43 (+0.56%)
     
  • Nasdaq

    15,680.11
    +228.81 (+1.48%)
     
  • Bitcoin USD

    66,679.45
    +643.59 (+0.97%)
     
  • CMC Crypto 200

    1,432.63
    +17.87 (+1.26%)
     
  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     
  • Gold

    2,336.20
    -10.20 (-0.43%)
     
  • Crude Oil

    82.88
    +0.98 (+1.20%)
     
  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     
  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     
  • Jakarta Composite Index

    7,110.81
    +36.99 (+0.52%)
     
  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Why Ocugen Stock Rose, Then Slipped Today

Why Ocugen Stock Rose, Then Slipped Today

Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. Like many Ocugen bulls, LeBoyer is most excited about Covaxin. This is the coronavirus vaccine candidate currently being developed by Bharat Biotech, the American company's partner in India, in collaboration with the Indian Council of Medical Research-National Institute of Virology.